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Abstract
Binge eating is a dysregulated form of feeding behavior that occurs in multiple eating disorders 
including binge-eating disorder, the most common eating disorder. Feeding is a complex 
behavioral program supported through the function of multiple brain regions and influenced by a 
diverse array of receptor signaling pathways. Previous studies have shown the overexpression of 
the opioid neuropeptide nociceptin (orphanin FQ, N/OFQ) can induce hyperphagia, but the role of 
endogenous nociceptin receptor (NOP) in naturally occurring palatability-induced hyperphagia is 
unknown. In this study we adapted a simple, replicable form of binge eating of high fat food 
(HFD). We found that male and female C57BL/6J mice provided with daily one-hour access 
sessions to HFD eat significantly more during this period than those provided with continuous 24 
hour access. This form of feeding is rapid and entrained. Chronic intermittent HFD binge eating 
produced hyperactivity and increased light zone exploration in the open field and light-dark assays 
respectively. Treatment with the potent and selective NOP antagonist SB 612111 resulted in a 
significant dose-dependent reduction in binge intake in both male and female mice, and, unlike 
treatment with the serotonin selective reuptake inhibitor fluoxetine, produced no change in total 
24-hour food intake. SB 612111 treatment also significantly decreased non-binge-like acute HFD 
consumption in male mice. These data are consistent with the hypothesis that high fat binge eating 
is modulated by NOP signaling and that the NOP system may represent a promising novel 
receptor to explore for the treatment of binge eating.
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1. Introduction
Feeding is a critical survival behavior for animal species across phylogeny, including 
mammals. In humans, this behavior is subject to dysregulation in multiple psychiatric 
disorders including depression, anxiety disorders, and eating disorders. Binge eating is a 
form of feeding that is defined by consumption of a large amount of food in a short amount 
of time paired with a sense of loss of control[1]. In humans, this pattern of feeding is 
accompanied by psychological components such as feelings of guilt or shame and is often 
preceded by anxiety or stress. The behavior of binge eating is moderately heritable (50–
60%) and is observed across a range of eating disorders presentations including binge-eating 
disorder, bulimia nervosa, and a binge-purge subtype of anorexia nervosa[2]. Genetic factors 
do not act alone, as environmental factors also contribute to liability[3].
Pharmacotherapeutic treatment strategies for binge eating including serotonin selective 
reuptake inhibitors such as fluoxetine or citalopram and dopamine transporter-targeted 
compounds like lisdexamphetamine[4,5]. Not all patients respond to these treatments, 
however, and side effects of these drugs limit their overall impact. Complementary 
pharmacological approaches are needed that target other signaling pathways engaged by 
binge eating, but our knowledge of the pathways that regulate binge eating behavior is 
incomplete.
Animal models have helped reveal complex neural networks and signaling pathways that act 
to increase or decrease feeding. Among the molecules that promote feeding are a host of 
neuropeptides including orexin, agouti related peptide, neuropeptide Y, melanin 
concentrating hormone, dynorphin, ghrelin, and the opioid-like molecule nociceptin[6]. 
Nociceptin/Orphanin (N/OFQ) FQ binds a single opioid-like g-protein coupled receptor 
(NOP/ORL1) with no affinity for mu, kappa, or delta opioid receptors[7–9]. It is a 17-amino 
acid peptide that it is encoded by the prepronociceptin gene[10] that is expressed widely 
throughout the brain in mice, rats, and humans [11–14]. Early studies demonstrated that the 
overexpression of nociceptin or NOP agonists throughout the brain or in specific brain 
nuclei can produce hyperphagia [15–20]. These gain of function experiments point to the 
capacity of nociceptin signaling to produce feeding behavior, but the role of the endogenous 
nociceptin signaling pathway in behaviorally induced binge eating behavior is unclear.
Recently, several groups have developed highly potent and selective peptide and non-
peptide-like NOP antagonists [17,19,21–24]. Early characterization demonstrated that the 
NOP antagonist SB 612111 could block the thermal hyperalgesic effects of nociceptin[23]. 
Further characterization of this compound demonstrated that it had no effect on chow 
hyperphagia induced by food deprivation, though it was capable of blocking 
intracerebroventricular N/OFQ-induced hyperphagia. In this study we used adapted models 
of binge eating in rats and mice generated by intermittent access to high fat food to test if 
nociceptin signaling is required for this form of hyperphagia[25,26]. Our results demonstrate 
that brief one-hour exposures to high fat containing food are sufficient to induce rapid and 
repetitive binge eating behavior in C57BL/6J mice; that chronic exposure to this form of 
binge eating is sufficient to induce changes in psychomotor behavior; and that intermittent 
high fat binge eating is modulated by nociceptin receptor signaling.
Hardaway et al. Page 2
Behav Brain Res. Author manuscript; available in PMC 2016 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2. Materials and Methods
2.1 Animals
Adult C57BL/6J (n = 89 males, 24 females, Jackson Labs, Bar Harbor, ME) were group 
housed in ventilated cages (Tecniplast) in a colony room on a standard 12:12 h light-dark 
cycle with lights on at 7 AM. One animal with malocclusion was excluded from the vehicle 
group in Figure 3E. Unless otherwise noted animals had ad libitum access to food and water. 
For measurements of food intake and intermittent access binge eating, animals were singly 
housed. Mice were acclimated to single housing for a week prior to any measurements or 
experiments. Food hoppers were fitted with a custom made trapezoidal plexiglas divider to 
provide segregated access to multiple types of food at once. Cage changes were minimized 
during feeding measurements to limit stress effects on food consumption. All procedures 
were approved by the Institutional Animal Care and Use Committee of the University of 
North Carolina at Chapel Hill and performed in accordance with the National Institute of 
Health's guide for the care and use of laboratory animals.
2.2 Intermittent access high fat binge protocol
To limit the effects of food deprivation, stress, or novelty-induced suppression of feeding, we 
adapted our model from a previously published model by Czyzyk et al.[25]. For our studies, 
individually housed mice were provided with either 1) ad libitum access to standard rodent 
chow (Harlan – 2020SX, caloric density = 3.1 kcal/gram) and high fat diet (HFD, Research 
Diets – 12492, 5.24 kcal/gram) or 2) ad libitum access to standard rodent chow and 1 hour 
daily intermittent access to HFD. Each day (11:00 AM, 4 hours into light cycle), body 
weights were measured and the overnight consumption of chow or HFD measured. Food 
was replenished daily for both food types and one-hour intake of both chow and HFD 
measured for both groups. At the end the hour, food weights were measured and the HFD 
removed from the intermittent access group. In this way we tracked consumption in the 
home cage during both intermittent and non-intermittent access sessions. All food 
consumption values are presented as normalized by the caloric density of the food divided 
by the body weight of the animal (kCal/g bodyweight).
2.3 Drugs and treatment design
SB 612111 (Tocris – cat no. 3573) was dissolved in DMSO and diluted in 0.9% sterile 
saline. Gentle heating at 45–50° C was used for 5 min after dissolution to ensure complete 
solubilization of the drug. 10 mg/kg stock was serially diluted in sterile saline to 3,1, or 0.1 
mg/kg. Fluoxetine (TCI chemicals – cat no. 56296) was dissolved directly in saline and 
injected at 30 mg/kg. All injections were intraperitoneal and injected at a volume of 10 
ml/kg 30 min. prior to the onset of binging. SB 612111 drug treatments were performed in a 
modified Latin squares design to randomize drug order effects with 2 days of vehicle 
injections between drug treatment days. Animals were handled and injected with vehicle for 
two days prior to the first drug treatment. Because we observed a continuing gradual 
escalation of high fat food consumption over time, baseline binge consumption over the 
course of SB 612111 treatment as depicted in Fig. 3 were calculated from at least 2 vehicle 
treatment days interspersed between every drug dose. For tests of SB 612111 effects on the 
first HFD exposure (Figure 3E), animals were handled and injected with vehicle solution for 
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three separate days before treatment with SB 612111 and HFD exposure. Drug carryover 
effects between days were only observed for Fluoxetine. We used vehicle dimethyl sulfoxide 
(DMSO) concentrations up to 2.5% without observing any effects on high fat diet 
consumption.
2.4 Open Field Assay
Behavioral effects of intermittent access binging were assessed in an independent cohort of 
mice (n = 10 per group) after 3 weeks of chronic intermittent or continuous HFD exposure. 
No drug treatments were performed with these mice and an ad libitum chow only control 
group was included. In a previous study, the behavioral effects of intermittent access binging 
were assessed; however, the behavioral assays were performed 24 hours after the completion 
of a weekly binge cycle [25]. We reasoned that the timing of the behavioral assays relative 
their binge behavior may represent an important factor and hypothesized that the expectation 
of HFD access would produce changes in anxiety-like behavior. After three weeks of stable 
daily intermittent binge eating, we performed the behavioral assays during the time they 
would normally binge eat (11 am), and provided intermittent access to HFD following the 
completion of these assays (afternoon). We did not observe any changes in binge HFD 
consumption during this period.
Mice were placed in a square white plexiglas arena measuring 20.5 in. on each side and their 
movement recorded using a CCD camera. Mice were allowed to explore the box for 20 min. 
Behavior was tracked using Ethovision XT (Noldus Information Technology), where center 
was defined as the middle half of the box in both the X and Y planes.
2.5 Elevated Plus Maze
Mice were placed in a standard design elevated plus maze and allowed to explore the open 
and closed arms for 5 minutes. Exploratory behavior was tracked as previously described in 
the open field section.
2.6 Light/Dark Box Conflict Assay
Mice were placed in two-sided chambers containing a dark enclosed side and a brightly lit 
open side and allowed to explore both sides for 15 min. Behavior was tracked as previously 
described in the open field section.
2.7 Statistics
Statistical analyses were performed in Prism 6.0e (GraphPad; La Jolla, CA). Details of 
analyses are described in the figure legends or in the Results. In Figures 1 and 3, we did not 
hypothesize any sex differences so we did not assess those differences, but the data are 
presented together for illustrative purposes. Figures were assembled in Adobe Illustrator.
Results
3.1 Establishment of a model of high fat binge eating
To determine novel receptor signaling contributions to high fat binge eating, we developed a 
simple, replicable form of binge eating that limits the impact of stress and food deprivation. 
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We adapted our model from a previous study that provided access to high fat food on a 
weekly cycle [25,27]. We modified this model to promote daily hyperphagia by providing 
intermittent access to a palatable food containing 60% fat by weight in 1 hour sessions in the 
home cages during the light cycle and 24 hour access to standard rodent chow (Figure 1A). 
Under these conditions, we observe a highly significant increase in the amount of high fat 
diet (HFD) consumed during the 1 hour access periods in intermittent (I-HFD) animals 
relative to animals that receive 24 hour continuous (C-HFD) access (Figure 1B, Males - RM 
two-way ANOVA: group effect - F (3, 75) = 163.8, p<0.001; time effect - F (14, 1050) = 
6.963, p<0.0001, group × time effect - F (42, 1050) = 3.599, p<0.0001; Females – RM two-
way ANOVA: group effect – F(1, 22) = 398.4, p<0.001; time effect – F(14,308) = 3.79, 
p<0.0001; group × time effect – F(14, 308) = 3.003, p<0.0001). Between group post hoc 
comparisons of these data reveal a highly significant difference between I-HFD and C-HFD 
mice even on the first day and each day thereafter during a two-week period in either male 
or female C57BL/6J mice. We observe no chow consumption during these one-hour access 
periods (data not shown). For the HFD consumed, within group post-hoc comparisons of the 
access days of the I-HFD group revealed a highly significant difference between the first 
day of HFD exposure and the subsequent days (Dunnett's multiple comparisons test, 
p<0.0001 for Days 2-14 compared to Day 1 for males, p<0.05 for Days 5–15 compared to 
Day 1 for females). We observed a concomitant reduction in home cage chow intake in male 
and female I-HFD mice (Figure 1C, Males - RM one-way ANOVA: F(4.510, 148.8) = 3.63, 
p = 0.0054; Females – RM one-way ANOVA: F(4.05, 44.55) = 15.97, p < 0.0001). Post hoc 
comparisons of the total chow intake reveal a significant difference between Day 1 and all 
subsequent days for female mice (Dunnett's multiple comparisons test of Day 2-14 to Day 
1), but did not reach significance for males that may be due to the high variance on Day 1. 
When we considered how the intermittent HFD intake related to their total intake (Binge 
Index), we observed a highly significant increase in the Binge Index for both male and 
female I-HFD mice (Figure 1D, Males - RM One-way ANOVA: F(5.298, 243.7) = 4.30, p = 
0.0007; Females – RM One-way ANOVA: F(5.174, 56.92) = 5.566, p = 0.0003). Post hoc 
comparisons of the Binge Index values over the first two weeks demonstrated a significant 
escalation for both male and female mice (Dunnett's multiple comparisons test of Days 2-14 
to Day 1). Under these conditions, C-HFD mice (either male or female) preferred the HFD 
and not chow and demonstrate stable elevated caloric intake(see below). Thus brief, daily 
one hour exposures to HFD are sufficient to engender increases in food intake that escalate 
from the first day of exposure.
Following the acquisition of this form of hyperphagia on Day 1, we observed that I-HFD 
mice quickly orient to the placement of HFD in their home cage and rapidly consume it. To 
test whether these intermittent access periods of HFD produce rapid consumption, we 
shortened the access period to either 30 min. or 10 min. Reduction of the access period 
length to either 30 or 10 min. produced a highly significant reduction in the magnitude of 
binge consumption in both males (Figure 1F, baseline: 0.148 +/− 0.0143, 30 min: 0.0932 +/
− 0.00937, 10 min: 0.0864 +/− 0.0146; RM one-way ANOVA: F (1.967, 17.70) = 10.06, p = 
0.0013) and females (baseline: 0.253 +/− 0.0109, 30 min: 0.203 +/− 0.0112, 10 min: 0.133 
+/− 0.0136; RM one-way ANOVA: F (1.876, 20.64) = 41.44, p <0.0001). However, these 
data also demonstrate that in both male and female I mice, more than half of the HFD 
Hardaway et al. Page 5
Behav Brain Res. Author manuscript; available in PMC 2016 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
consumption occurs rapidly within the first 10 min of the access period (Males – 58.42 +/
− 14.41 % and Females – 52.63 +/− 7.17 %).
To determine the effect of chronic intermittent access HFD binging on body weight, we 
compared average body weights between I-HFD and C-HFD mice after 3 weeks. For both 
sexes, we observed that C-HFD mice exhibit a significant percent change elevation in body 
weight relative to I-HFD mice (Figure 1G, Unpaired student's t test, Males – p = 0.0052, 
Females – p < 0.0001). We also observed that the total intake in C-HFD mice was 
significantly elevated for both male and female mice (Figure 1E, Unpaired student's t test, 
Males – t=2.965, df=38, p < 0.0001; Females – t=5.541, df=22, p = 0.0187). Correlational 
assessments of home cage chow intake with binge HFD intake in the I-HFD mice revealed a 
significant inverse correlation between the two, with stronger binge eaters consuming less 
chow in their home cage over a 24-hour period (Figure 1H, slope significantly non-zero, F = 
6.949, p =0.0158).
Overall, we found in both male and female C57BL/6J mice that daily short 1-hour exposures 
to HFD produce significant increases in food intake that escalates over time concomitant 
with a decrease in home cage chow intake. I-HFD mice gain less weight and demonstrate a 
lower overall daily caloric intake than C-HFD mice.
3.2 Behavioral effects of chronic intermittent high fat binge eating
We hypothesized that chronic daily intermittent HFD binge eating might produce a state of 
expectant anxiety for the HFD. In a separate cohort of animals that had undergone 3 weeks 
of either ad libitum chow, continuous HFD, or intermittent HFD; we assessed anxiety-like 
behavior using three established locomotor assays that capitalize on mice innate preference 
for dark enclosed spaces: response to an open field, a light-dark box conflict assay, and an 
elevated plus maze.
In the open field assay (Figure 2A), we observed an overall main effect in distance traveled 
(Figure 2B, Chow: 9556 +/− 552 cm, C-HFD – 8576 +/− 299, I-HFD – 10492 +/− 450.4, 
one-way ANOVA, F = 4.873, p = 0.0156). Post hoc comparisons revealed a highly 
significant increase in distance traveled in I-HFD mice relative to C-HFD mice (Sidak's 
multiple comparisons test, p = 0.0085), but not between I-HFD and ad lib controls (p = 
0.2653). We observed no significant overall effects in the time spent in the center (Figure 
2C, Chow: 67.43 +/− 5.51, C-HFD: 79.58 +/− 7.391, I-HFD: 84.99 +/− 5.92, one-way 
ANOVA, F = 2.021, p < 0.1520), the number of center entries (Figure 2D, Chow: 49.20 +/
− 3.809, C-HFD: 52.00 +/− 2.42, I-HFD: 61.80 +/− 6.189, one-way ANOVA, F = 2.238, p 
= 0.1261), or the latency to enter the center (data not shown).
In the light/dark conflict assay (Figure 2E), we observed an overall strong nonsignificant 
trend in the duration spent in the light side of the box (Figure 2F, Chow: 428 +/− 41.73 s, C-
HFD: 354.7 +/− 32.72 s, I-HFD: 470.4 +/− 19.68 s, one-way ANOVA, F = 3.216, p = 
0.0559), but post-hoc tests revealed a significant increase in the I-HFD group relative to the 
C-HFD group in light side duration (p =0.0387) but not between I-HFD and chow controls. 
There was no significant effect in the latency to enter the light side (Figure 2G, Chow: 42.71 
+/− 11.21 s, C-HFD: 37.46 +/− 13.15 s, I-HFD: 18.38 +/− 5.289 s, one-way ANOVA, F = 
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1.505, p = 0.2401) or the number of entries (Figure 2H, Chow: 25.70 +/− 2.196 s, C-HFD: 
24.90 +/− 1.71 s, I-HFD: 26.40 +/− 2.088 s one-way ANOVA, F = 0.1394, p = 0.8705).
In the elevated plus maze (Figure 2I), we observed no overall main effect on the time spent 
in distance traveled (Figure 2J, Chow: 1849 +/− 113.3 cm (SEM), C-HFD: 1955 +/− 101.7 
cm, I-HFD: 1877 +/− 102.3 cm, one-way ANOVA, F = 0.26, p = 0.7730), % open arm time 
(Figure 2K, Chow: 24.01 +/− 1.906, C-HFD: 24.22 +/− 2.647, I-HFD: 29.09 +/− 3.172, 
one-way ANOVA, F = 1.219, p = 0.3118), or the probability of an open arm entry (Figure 
2L, Chow: 0.2398 +/− 0.02175, C-HFD: 0.2597 +/− 0.01096, I-HFD: 0.2643 +/− 0.03673, 
one-way ANOVA, F = 0.2542, p = 0.7775).
In total, we observed that chronic intermittent access to HFD produced significant overall 
effects in distance traveled in the open field driven by differences in I-HFD and C-HFD 
mice, but no effects on center time or entries. We observed no overall effects in the light-
dark box or the elevated plus maze between ad libitum chow, I-HFD, or C-HFD mice.
3.3 Nociceptin receptor signaling contributions to intermittent HFD binge eating
Having established a simple, replicable model of HFD binge eating, we explored whether 
endogenous nociceptin receptor signaling modulates binge eating. We administered a potent, 
highly selective nociceptin receptor antagonist SB 612111 intraperitoneally in either C-HFD 
or I-HFD animals having established a stable baseline of HFD consumption. Although low 
doses of SB 612111 had no effect on binge consumption, we observed a significant overall 
effect of drug treatment and a significant drug by group interaction (RM two-way ANOVA; 
drug effect: F (5, 90) = 18.99, p < 0.0001; group effect: F (1, 18) = 106.7, p<0.0001; group × 
drug effect: F (5, 90) = 14.36, p < 0.0001) in males (Figure 3A). Post-hoc comparisons 
revealed a significant reduction in binge consumption in I-HFD mice relative to baseline 
with 10 mg/kg SB 612111 (Dunnett's post test, p = 0.0004, 36.2% decrease, see inset). We 
observed no significant effect of SB 612111 in C-HFD mice. After a one-week period of 
washout and continued intermittent access HFD binging, we replicated the decrease in binge 
consumption with 10 mg/kg SB 612111 within this cohort of mice (data not shown) and in a 
separate cohort of untreated male I-HFD mice (data not shown). To determine whether SB 
612111 has a differential effect on binge consumption during the acquisition of intermittent 
access binge eating behavior, we used a separate cohort of only I-HFD male mice receiving 
either vehicle or 10 mg/kg SB 612111 and observed a significant reduction in HFD 
consumption on their first day of HFD exposure (Figure 3E, Vehicle: 0.0804 +/− 0.025, SB 
612111: 0.0439 +/− 0.0316; Unpaired Student's t test, t= 3.054, df = 21 p = 0.006).
In a separate cohort of female I-HFD and C-HFD mice, we observed a similar overall effect 
(Figure 3B, RM two-way ANOVA; drug effect: F (5, 110) = 56.99, p <0.0001; group effect: 
F (1, 22) = 325.7, p<0.0001; group × drug effect: F (5, 110) = 49.97, p<0.0001) where 10 
mg/kg SB 612111 produced a highly significant effect on binge HFD consumption 
(Dunnett's post test, Baseline: 0.253 +/− 0.011 vs. 10 mg/kg SB 612111: 0.200 +/− 0.014, 
p=0.0013, 20% decrease see inset). As a positive control, we also tested the effect of 30 
mg/kg of the serotonin selective reuptake inhibitor fluoxetine (FLX) in both male and female 
I-HFD and C-HFD mice, as this has been shown to robustly reduce binge feeding in 
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multiple preclinical studies and is commonly prescribed to treat binge-eating disorder [4,25]. 
Post tests revealed a highly significant and nearly complete reduction of binge consumption 
with FLX treatment (Males: Baseline = 0.14 +/− 0.012 vs. FLX = 0.01 +/− 0.007; Females: 
Baseline = 0.253 +/− 0.011 vs FLX = 0.006 +/− 0.002, Dunnett's post test p <0.0001 for 
both groups).
These data demonstrate that SB 612111 and FLX both significantly reduce binge HFD 
consumption in I-HFD mice. We further explored the specificity of these effects within the 
context of total food intake. Analyses of total food intake in both C-HFD and I-HFD mice 
revealed a significant effect of drug and drug × group interaction in males (RM two-way 
ANOVA, drug effect: F (5, 90) = 38.72, p < 0.0001; group effect: F (1, 18) = 2.614, p = 
0.5392; group × drug effect: F (5, 90) = 11.03, p < 0.0001) and significant effect of drug in 
females (RM two-way ANOVA, drug effect: F (5, 110) = 22.87, p <0.0001; group effect: F 
(1, 22) = 3.572, p = 0.0757, drug × group effect: F (5, 110) = 1.933, p = 0.0946). However 
post-hoc analyses revealed that there was no significant effect of SB 612111 treatment on 
total intake relative to baseline in either C-HFD or I-HFD mice, but a highly significant 
reduction in total intake with FLX treatment in both males (Dunnett's post test; I: Baseline = 
0.364 +/− 0.009 vs. FLX = 0.276 +/− 0.015; C-HFD: Baseline = 0.411 +/− 0.007 vs. FLX = 
0.117 +/− 0.021, p < 0.01 in either post test) and females (Dunnett's post test; I-HFD: 
Baseline = 0.508 +/− 0.01 vs. FLX = 0.346 +/− 0.03; C-HFD: Baseline = 0.538 +/− 0.018 
vs. FLX = 0.298 +/− 0.033, p < 0.001 in either post test). Furthermore, 30 mg/kg FLX 
produced acute reductions in body weight in both males and female mice (data not shown). 
These data demonstrate that SB 612111 treatment had no effect on total 24-hour food intake 
while FLX treatment produced a significant reduction in total 24-hour food intake.
In summary, the NOP/Oprl1 antagonist, SB 612111, produced a significant, dose-dependent 
decrease in HFD binge consumption in the I-HFD group with no effect total intake. SB 
612111 had no effect on the C-HFD group in either binge or total food intake. Treatment 
with the SSRI fluoxetine blocked binge consumption in the I-HFD group, while also 
reducing total food intake in both the I-HFD and C-HFD. Similar effects were observed in 
both male and female C57BL/6J mice. Additionally, we observed that SB 612111 treatment 
significantly decreases HFD consumption in acute intermittent access.
4. Discussion
Binge eating is a complex, multifaceted motivated behavior that is subserved by multiple 
neural circuits and receptor signaling pathways. One challenge associated with dissecting 
this complex signaling network is the dearth of simple behavioral models of binge eating 
that enable experimenters to capitalize on the development of highly specific and reversible 
pharmacological and neural circuit tools in genetically-modified laboratory mice. 
Additionally, many behavioral paradigms to dissect feeding or binge eating also suffer from 
unwanted floor effects through novelty-induced suppression of feeding by introducing the 
animal into novel testing arenas.
In this study, we adopted a simple, replicable model of home cage binge eating based on 
palatability-induced hyperphagia. Our data show that intermittent one-hour access to a high-
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fat containing food produces a robust increase in intake even on the first day of access. This 
high fat binge eating escalates substantially after the first day and continues over multiple 
weeks. Combined with a concomitant decrease in home cage chow intake over this period, 
animals provided with chronic intermittent HFD intake will increase their one-hour binge 
intake during the first two weeks until it comprises more than 40% of their total daily caloric 
intake. Importantly, our data demonstrate that this form of food consumption is rapid and 
entrained similar to clinical definitions of binge eating in humans.
Multiple models of binge eating of sweet, fat, or sweet-fat food mixtures have been 
developed that incorporate different forms of diet cycling, access limitations, stress, or food 
deprivation [25,28–33]. Each of these models has unique strengths and weaknesses. In our 
study, we chose to capitalize on binge eating produced by providing intermittent access to 
palatable food that occurs independent of food restriction and stress (see chapter 4 Corwin et 
al. for review)[34] and has been observed in rats and mice [25]. Importantly, we used 
C57BL/6J mice; the most common strain of laboratory mice that is now a rich resource of 
genetically altered strains to map physiological and neural circuit contributions to behavior. 
This strain is so notoriously difficult to use in operant self-administration studies, so we 
chose to use the animal's home cage as the arena for our behavioral manipulations. 
Additionally, we chose not to incorporate food-deprivation because of its effects on gene 
expression of prepronociceptin and NOP[35] and because it has been demonstrated that SB 
612111 has no effect on food-deprivation induced hyperphagia[23]. We hypothesized that 
although food-deprivation induced hyperphagia and palatability-induced hyperphagia are 
behaviors that share some common neural substrates, circuit-dependent fast-acting 
neurotransmission and neuromodulatory signaling mechanisms are discretely engaged 
through these forms of feeding. Additionally, many previous studies use food containing 
some amount of sucrose or even cafeteria diets [36–40]. We preferred a model that could 
selectively probe the receptor signaling pathways that are engaged by fat. Lastly, animal 
models of binge eating using both rats and mice incorporate multiple aspects of the 
behavioral phenomenon including stress, diet cycling, and palatable food access. Other 
cognitive and affective features of binge eating (e.g., guilt, distress), which vary 
considerably across humans, are less capturable by animal models. We posit that the primary 
utility of animal models is in generating time-locked, replicable binge-like hyperphagia, the 
core behavioral phenotype of binge eating in humans.
Using our model of chronic intermittent HFD binge eating, we determined whether this 
course of binge eating had any effects on anxiety like behavior. After three weeks of binge 
eating, we assayed performance in the open-field, elevated plus maze (EPM), and light-dark 
conflict assays. During this time, we maintained binge conditions following the behavioral 
assays to avoid possible withdrawal effects. We observed a significant increase in the 
distance traveled in the open field and an increase in the time spent in the light side of the 
light-dark box. The light-dark findings are broadly consistent with a previous study[31]; 
although, that study used rats and the light aversive side of the compartment was paired with 
the palatable binge food. We observed no significant effect on measures of anxiety with the 
EPM. Our data are consistent with a previous study[25] that used a different cycling of HFD 
access and took behavioral measures 24 hours after the last binge cycle. Overall the data did 
not support our hypothesis that chronic intermittent binge eating produces expectant anxiety 
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for the HFD, as we observed no decrease in open field center time, light side time or entries, 
or open arm time in the EPM. However, it is still possible that withdrawal from intermittent 
HFD binge eating is capable of producing anxiety.
One limitation of our study is that we cannot rule out that the effects we saw on locomotion 
in either the open field or light-dark box might be produced by changes in bodyweight in the 
C group. One study using C57BL/6J mice reported an increase in anxiety and depressive-
like behavior after chronic HFD exposure vs. low-fat diet exposure; however, measures of 
locomotion like the distance traveled or velocity were not reported and there was no ad lib 
chow as in our study[41]. A similar study in female rats exposed to chronic HFD with 
similar caveats was recently published[42]. We explored the possibility of body weight 
effects on locomotion and observed no linear relationship between body weight and open 
field velocity (data not shown). Additionally, although there was a significant gain in body 
weight as expressed as percent change in the C-HFD group after 3 weeks, this effect is very 
subtle relative to common models of diet-induced obesity after 6–8 weeks [43]. Therefore 
we believe it unlikely that the differences between the I and C HFD groups in the open field 
and light dark assays derive from subtle changes in body weight produced by 3 weeks of 
intermittent or continuous HFD exposure. Lastly, we speculate that the timing of binge 
eating manipulations on mice and their effects on anxiety-like behavior may represent an 
important component in the experimental design. Future studies that integrate the binge 
eating and behavior into a shorter space of time are necessary to explore this hypothesis.
Anxiety disorders and eating disorders that include binge eating are highly comorbid 
[44,45], but the antecedent nature of these associations clinically are incompletely 
understood. Our data show that in mice, chronic maintained HFD binge eating does not 
produce anxiety-like behavior. Instead, we speculate that the subtle hyperactivity we observe 
in the I-HFD group is more consistent with elevated foraging behavior or behavioral 
disinhibition. Our data do not preclude the possibility that more chronic withdrawal from 
HFD can produce anxiety. Further studies in mice are necessary to explore the relationship 
between anxiety and binge eating.
Nociceptin is an opioid heptadecapeptide that binds a single g-protein coupled receptor 
(NOP/Oprl1) with minimal affinity for μ, κ, δ opioid receptors. Central injections of this 
peptide or NOP agonists produces a dose-dependent increase in feeding behavior 
[15,17,19,20,46–48], and chronic infusions of this peptide are capable of producing changes 
in body weight [49]. Interestingly, three studies demonstrate that 1) N/OFQ induced 
hyperphagia is present only in Sprague-Dawley rats that have been previously established as 
“fat-preferring”; 2) NOP/Oprl1 knockout mice consume significantly less high-fat 
containing food than their wildtype littermate controls, and 3) that a novel NOP antagonist 
LY2940094 increases lipid utilization metabolism in mice [50–52]. Taken together, we 
hypothesized that NOP/Oprl1 signaling is recruited during and required for binge eating of 
high fat containing foods. Consistent with our hypothesis, we observed that treatment with 
the highly potent and selective NOP/Oprl1 antagonist SB 612111 produced a dose-
dependent decrease in intermittent HFD binge eating. We selected 10 mg/kg as our highest 
dose as this dose does not impact food-deprivation induced hyperphagia [23]; however, 
doses as high as 30 mg/kg are tolerated with no ill effects in C57BL/6 mice [53].
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Importantly, we did not observe a change in the total 24-hour intake of mice treated with SB 
612111 in either I-HFD or C-HFD mice. One reason for the lack of effect in C-HFD mice 
may be due to the pharmacokinetic properties of a single-dose of SB 612111 precluding its 
anorexigenic effect during the dark period where the majority of the HFD is consumed. In 
contrast, high doses of fluoxetine (FLX) almost completely blocked binge consumption with 
a concomitant reduction in the animal's 24-hour total intake. This is consistent with a 
previous study [25] and a recent study that used the 5HT2C agonist mCPP [52]; however, we 
attribute this reduction in overall food intake to the potent acute anxiogenic capacity of these 
doses of FLX [54–56]. Although SSRIs like FLX are one of the most common drugs used to 
treat binge eating disorder [4](Also see AHRQ Systematic Review - Management and 
Outcomes of Binge Eating Disorder), not all patient's symptoms improve with SSRI 
treatment[4]. Novel drugs with more selective modes of action and potential macronutrient 
selectivity might be more effective for those who binge eat on fat-rich foods.
At present, the exact physiological mechanism of SB 612111's effects are unclear, however 
present literature supports a model by which this drug acts on NOP/Oprl1 in the central 
nervous system[9,48]. In the brain, there are several brain regions rich in NOP expression 
and that modulate binge eating that represent compelling targets for future investigation of 
SB 612111 effects including hypothalamic nuclei like the paraventricular, lateral, 
ventromedial and arcuate nuclei[46,57–61], midbrain monoaminergic nuclei like the ventral 
tegmental area and dorsal raphe nucleus[62–66], and extended amygdala structures such as 
the bed nucleus of the stria terminalis[67] and central amygdala[35]. As drugs that modulate 
5HT signaling have been shown to have robust anorexigenic effects[68], an intriguing 
explanation for SB 612111's mechanism is through its interaction with the brain's 
serotonergic system. Future studies are necessary, however, to test these hypotheses.
Recently, a novel set of orally available highly selective NOP/Oprl1 antagonists have been 
developed, and one of these compounds, LY2940094, has subnanomolar potency for human 
NOP, has sustained brain occupancy, and has been tested in rodent models of feeding 
[52,69]. This compound was found to reduce fasting-induced hyperphagia of chow in 
wildtype 129S6 mice, but not those with genetic deletion of the Oprl1 gene (NOP KO mice). 
Additionally, LY2940094 reduced the consumption of high fat food measured acutely over a 
5-hour exposure and weight gain produced by 3 days of these exposures. They also showed 
that LY2940094 reduced intake of HFD in diet-induced obese models in rats and mice, and 
that this drug reduced the respiratory quotient in mice with access to HFD in cages that 
permit the measurement of O2 utilization and CO2 production. This last point reflects that 
NOP antagonism with LY2940094 promotes fat utilization in addition to reducing HFD 
intake. Our results provide convergent data that antagonism of NOP reduces HFD intake 
either in a single acute exposure or in a daily intermittent access schedule in both male and 
female C57BL/6J mice. Taken together, our two studies demonstrate that antagonism of 
NOP is a compelling target for the treatment of binge eating and obesity, and that further 
studies are needed to understand the hypophagic mechanism of action of NOP antagonists in 
the brain.
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5. Conclusions
We conclude that short daily one-hour access periods to high fat containing food are 
sufficient to induce rapid, replicable binge-like consumption. Chronic intermittent binge 
eating produces changes in psychomotor behavior. Lastly, treatment with NOP/Oprl1 
antagonists reduced HFD binge eating in the intermittent access model.
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Figure 1. Intermittent daily access to HFD promotes large, rapid consumption
A. Schematic of home cage paradigm for continuous (left) vs intermittent (right) access to 
high fat food in C57BL6/J mice. Chow is ad libitum. Access to HFD was provided at 11 am. 
B. Normalized consumption (kCal/ g bodyweight) of the HFD during the one-hour access 
period for male (black) and female (red) mice under continuous (closed symbols) or 
intermittent (open symbols) access conditions over the first two weeks. Within both the male 
and female group, data were analyzed by RM two-way ANOVA (n for each group: I-HFD 
male = 35, C-HFD male = 20, I-HFD female = 12, C-HFD female = 12, see Results for 
details). The I-HFD group consumed significantly more food during this access period than 
the C-HFD group for both male and female mice. C. Normalized consumption of the home 
cage chow (kCal/ g bodyweight) for the male and female I-HFD groups over the first two 
weeks. Within both the male and female group, data were analyzed by RM one-way 
ANOVA (n for each group: I-HFD male = 35, I-HFD female = 12, see Results for details). 
D. Fractional intake of the HFD for the male and female HFD group (Binge Index) during 
the first two weeks. Within both the male and female group, data were analyzed by RM one-
way ANOVA (n for each group: I-HFD male = 35, I-HFD female = 12, see Results for 
details). We observed a significant escalation in the Binge Index for both groups. E. Total 
caloric intake for male and female C-HFD and I-HFD groups. Data were analyzed by 
Unpaired student's t test(see Results for details). We observed a significant increase in 
caloric intake in both male and female C-HFD mice. F. After establishing a stable baseline 
of consumption in the I-HFD group, we decreased the access period length for the 
intermittent group from 60 min. to 30 min and 10 min. Within both the male and female 
group, data were analyzed by one-way ANOVA (n = 10 males and 12 females; see text for 
details). G. Percent change in bodyweight in males and females for I vs C mice. Continuous 
mice gain significantly more bodyweight than intermittent mice. Data were analyzed using 
an unpaired student's t test. H. Correlational analyses of binge HFD intake vs home cage 
Hardaway et al. Page 17
Behav Brain Res. Author manuscript; available in PMC 2016 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
chow intake in I-HFD mice. Male and Female animals were pooled. Data were fit using 
linear regression. Slope was significantly non-zero (F = 6.949, p = 0.0158). For all panels * 
= p < 0.05, ** = p < 0.01, *** = p < 0.001, and **** p < 0.0001.
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Figure 2. Intermittent HFD binging effects on anxiety and psychomotor behavior
A. Open field apparatus. B. Distance traveled in the open field (cm) over 20 min. There is a 
significant overall effect of group and I mice travel significantly more than C mice. C. Time 
spent in the center of the open field. There is no significant effect on center time. D. Center 
entries. E. Light/Dark conflict box F. Time spent in the light side of the light/dark box. 
Significant overall group effect (see results) with a significant difference between I and C 
mice. G. Latency to enter the light side. No significant group difference H. Total number of 
entries into the light side. No significant group differences. I. Elevated Plus Maze (EPM). J. 
Distance traveled in the EPM. No significant group differences. K. % Open arm time in the 
EPM. No significant group differences. L. Probability of an open arm entry in the EPM. No 
significant group differences. For all measures, data were analyzed by one-way ANOVA 
with Sidak's multiple comparisons test. See Results for further information on the statistical 
analyses. n = 10/ group for each assay.
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Figure 3. SB 612111 treatment reduces binge consumption, but not total 24 hour intake
A. Normalized binge intake in male mice treated with SB 612111 and 30 mg/kg fluoxetine 
(FLX). Drug Treatments were performed as described in the Methods. SB 612111 treatment 
produced a dose-dependent reduction in binge intake with 10 mg/kg SB 612111 producing a 
near 40% reduction in consumption intermittent mice (inset). There was no significant effect 
on continuous mice. B. Normalized binge intake in female mice treated with SB 612111 and 
30 mg/kg FLX. SB 612111 produced a dose dependent reduction in binge intake with 10 
mg/kg producing over 20% reduction in intake. There was no significant effect on 
continuous mice. C. Normalized 24 hour total intake in male mice treated with SB 612111 
and 30 mg/kg fluoxetine (FLX). SB 612111 had no effect on total intake in either 
intermittent or continuous male mice. FLX produced a significant reduction in total intake in 
either group. D. Normalized 24 hour total intake in female mice treated with SB 612111 and 
30 mg/kg fluoxetine (FLX). SB 612111 had no effect on total intake in either intermittent or 
continuous female mice. FLX produced a significant reduction in total intake in either 
group. For all panels, data were analyzed by a repeated measures two-way ANOVA with 
Dunnett's multiple comparison test to the baseline measurements of binge intake and total 
intake. E. HFD intake in first one-hour exposure to HFD in animals treated with vehicle or 
10 mg/kg SB 612111 (n = 12/group). SB 612111 produced a highly significant reduction in 
HFD intake.
Hardaway et al. Page 20
Behav Brain Res. Author manuscript; available in PMC 2016 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
